MA40801A1 - Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 - Google Patents

Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Info

Publication number
MA40801A1
MA40801A1 MA40801A MA40801A MA40801A1 MA 40801 A1 MA40801 A1 MA 40801A1 MA 40801 A MA40801 A MA 40801A MA 40801 A MA40801 A MA 40801A MA 40801 A1 MA40801 A1 MA 40801A1
Authority
MA
Morocco
Prior art keywords
antibody
bispecific antibodies
binding specifically
antibodies binding
relates
Prior art date
Application number
MA40801A
Other languages
English (en)
Inventor
Jana Albrecht
Cédric Barriere
Christian Beil
Jochen Beninga
Chantal Carrez
Stéphane Guerif
Katja Kroll
Christian Lange
Cendrine Lemoine
Wulf-Dirk Leuschner
Ercole Rao
Marion Schneider
Marie-Cécile Wetzel
Peter Wonerow
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA40801A1 publication Critical patent/MA40801A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une protéine de liaison de type anticorps se liant spécifiquement à cd3 et se liant de façon spécifique à au moins un autre antigène, par exemple cd123. La présente invention concerne également une protéine de liaison de type anticorps se liant spécifiquement à cd123 et se liant de façon spécifique à au moins un autre antigène. L'invention concerne en outre des anticorps anti-cd3 et des anticorps anti-cd123. L'invention concerne également des compositions pharmaceutiques com
MA40801A 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 MA40801A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305077 2015-01-23
PCT/EP2016/051386 WO2016116626A1 (fr) 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Publications (1)

Publication Number Publication Date
MA40801A1 true MA40801A1 (fr) 2018-07-31

Family

ID=52434717

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40801A MA40801A1 (fr) 2015-01-23 2016-01-22 Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123

Country Status (36)

Country Link
US (3) US20180057597A1 (fr)
EP (3) EP4039710A3 (fr)
JP (3) JP6817211B2 (fr)
CN (3) CN114230667A (fr)
AR (1) AR103488A1 (fr)
AU (2) AU2016210068B2 (fr)
BR (1) BR112017014805A2 (fr)
CA (1) CA2974453A1 (fr)
CL (2) CL2017001866A1 (fr)
CO (1) CO2017008462A2 (fr)
CR (1) CR20170383A (fr)
DO (1) DOP2017000160A (fr)
EA (1) EA201791666A1 (fr)
EC (1) ECSP17054182A (fr)
ES (1) ES2824167T3 (fr)
GT (1) GT201700162A (fr)
HR (1) HRP20201517T1 (fr)
HU (1) HUE052011T2 (fr)
IL (2) IL299975A (fr)
LT (1) LT3247725T (fr)
MA (1) MA40801A1 (fr)
MX (3) MX2017009535A (fr)
MY (1) MY191964A (fr)
NZ (1) NZ734803A (fr)
PE (1) PE20171764A1 (fr)
PH (1) PH12017501190A1 (fr)
PL (1) PL3247725T3 (fr)
PT (1) PT3247725T (fr)
RS (1) RS60916B1 (fr)
SG (2) SG11201705925PA (fr)
SI (1) SI3247725T1 (fr)
TN (3) TN2018000324A1 (fr)
TW (3) TW202402802A (fr)
UA (1) UA126269C2 (fr)
UY (1) UY36536A (fr)
WO (1) WO2016116626A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UA126269C2 (uk) 2015-01-23 2022-09-14 Санофі АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3819310A1 (fr) 2015-10-25 2021-05-12 Sanofi Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3471754A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anticorps anti-pd-l1
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
BR112019005333A2 (pt) 2016-09-21 2019-06-11 Aptevo Research And Development Llc proteínas de ligação a cd123 e composições e métodos relacionados
EP3541846A1 (fr) 2016-11-16 2019-09-25 Ablynx NV Polypeptides de recrutement de lymphocytes t capables de se lier à cd123 et tcr alpha/bêta
US11618785B2 (en) * 2016-12-22 2023-04-04 Daiichi Sankyo Company, Limited Anti-CD3 antibody and molecules comprising the antibody
AU2018218753A1 (en) * 2017-02-07 2019-09-26 Daiichi Sankyo Company, Limited Anti-GPRC5D antibody and molecule containing same
EA201892312A1 (ru) 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки
EP3409322A1 (fr) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Procédés de traitement
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
WO2019018538A1 (fr) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anticorps recombinants se liant à cd123
CA3074130A1 (fr) * 2017-09-21 2019-03-28 WuXi Biologics Ireland Limited Nouveaux anticorps anti-cd3epsilon
EP4249068A3 (fr) 2017-10-10 2023-11-22 Sanofi Anticorps anti-cd38 et procédés d'utilisation
WO2019075405A1 (fr) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation
BR112020008127A2 (pt) * 2017-10-27 2020-10-13 Pfizer Inc. anticorpos e conjugados de anticorpo-fármaco específicos para cd123 e seus usos
SG11202006410WA (en) 2018-01-12 2020-08-28 Genzyme Corp Methods for the quantitation of polypeptides
JP7337079B2 (ja) * 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
SG11202011270QA (en) * 2018-05-24 2020-12-30 Janssen Biotech Inc Anti-cd3 antibodies and uses thereof
WO2019237350A1 (fr) * 2018-06-15 2019-12-19 康源博创生物科技(北京)有限公司 Anticorps anti-cd123, son procédé de préparation et son utilisation
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
US20210269525A1 (en) * 2018-06-29 2021-09-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ANTI-CD3e ANTIBODIES AND USES THEREOF
EP4268831A3 (fr) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
KR20210148076A (ko) * 2018-12-11 2021-12-07 큐32 바이오 인크. 보체 연관 질환을 위한 융합 단백질 작제물
US11965030B2 (en) * 2018-12-24 2024-04-23 Sanofi Multispecific binding proteins with mutant fab domains
WO2020210392A1 (fr) * 2019-04-09 2020-10-15 Sanofi Protéines de liaison trispécifiques, procédés et utilisations connexes
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2020232247A1 (fr) 2019-05-14 2020-11-19 Provention Bio, Inc. Procédés et compositions pour la prévention du diabète de type 1
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4013796A4 (fr) * 2019-08-17 2023-08-02 IGM Biosciences Inc. Molécules de liaison anti-cd123 bispécifiques multimères et leurs utilisations
JP7227895B2 (ja) * 2019-12-23 2023-02-22 株式会社堀場製作所 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット
EP4090365A1 (fr) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Protéines de liaison à l'antigène se liant de manière spécifique à prame
CN111171155B (zh) 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 抗cd3和cd123双特异性抗体及其用途
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
CR20220594A (es) * 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
CA3206883A1 (fr) 2020-12-31 2022-07-07 Sanofi Agents d'activation de cellules tueuses naturelles (nk) multifonctionnels se liant a nkp46 et cd123
WO2022150792A1 (fr) * 2021-01-11 2022-07-14 Soteria Biotherapeutics, Inc. Compositions d'engagement de lymphocytes t de dimérisation chimique à base d'indinavir
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
WO2022184805A1 (fr) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité
CN117120471A (zh) * 2021-03-23 2023-11-24 广州凌腾生物医药有限公司 结合cd3的多特异性抗原结合蛋白及其用途
JP2024518378A (ja) 2021-05-05 2024-05-01 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
BR112023022584A2 (pt) 2021-05-27 2024-01-09 Sanofi Sa Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023061419A1 (fr) * 2021-10-12 2023-04-20 Concept To Medicine Biotech Co., Ltd. Anticorps anti-cd3 avec réactivité croisée vis-à-vis des protéines humaines et de cynomolgus
WO2023072217A1 (fr) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Protéines de fusion ciblant cd3 et cd47
CA3233696A1 (fr) 2021-11-03 2023-05-11 Joachim Koch Liants de cd16a bispecifiques
EP4198052A1 (fr) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides et protéines de liaison d'antigène pour utilisation dans l'immunothérapie contre le carcinome hépatocellulaire fibrolamellaire (fl-hcc) et autres cancers
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023150518A1 (fr) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Vecteurs lentiviraux ciblant cd3 et leurs utilisations
WO2023183600A1 (fr) * 2022-03-25 2023-09-28 Washington University Systèmes et procédés de surveillance de l'efficacité d'un traitement cytotoxique
TW202346337A (zh) 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023250434A2 (fr) * 2022-06-22 2023-12-28 The Regents Of The University Of Michigan Compositions et méthodes de traitement d'ides ciblés de troubles liés à l'igg
WO2024044655A1 (fr) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Administration de protéines hétérologues
WO2024061352A1 (fr) * 2022-09-23 2024-03-28 广州凌腾生物医药有限公司 Protéine de liaison à l'antigène isolée et son utilisation
WO2024088987A1 (fr) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
WO2024119157A1 (fr) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244A (en) 1837-06-30 Edward flint
US5204A (en) 1847-07-24 james cantelo
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0563296B1 (fr) 1990-12-20 1999-03-17 Ixsys, Inc. Optimalisation de proteines de liaison
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994019478A1 (fr) 1993-02-22 1994-09-01 The Rockefeller University Production de retrovirus exempts d'auxiliaires, a titre eleve par transfection transitoire
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
EP0971952A2 (fr) 1997-04-10 2000-01-19 Royal Netherlands Academy of Arts and Sciences Reactifs pour diagnostics et procede correspondant
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
AU5003001A (en) 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
CN1984931B (zh) * 2004-06-03 2012-11-28 诺维莫尼公司 抗-cd3抗体及其使用方法
KR101363120B1 (ko) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
CN101687915B8 (zh) * 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
NO2195023T3 (fr) 2007-08-29 2018-08-04
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
EP2949673A1 (fr) 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-il-3ra destiné à être utilisé dans le traitement d'une tumeur sanguine
JP6018507B2 (ja) 2010-02-17 2016-11-02 シーエスエル、リミテッド Ｉ型インターフェロン産生細胞を標的化するための組成物及び方法
US8569450B2 (en) * 2010-03-03 2013-10-29 Health Research Inc. CD3 epsilon immunogens and antibodies
US8920803B2 (en) * 2010-06-15 2014-12-30 Csl Limited Immunotherapeutic method involving CD123 (IL-3Rα) antibodies and immunostimulating complex
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
KR20190105112A (ko) 2011-05-21 2019-09-11 마크로제닉스, 인크. 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
CN102796198A (zh) 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3的融合蛋白、制备方法及其用途
CN102796199A (zh) * 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
EP2809682B1 (fr) 2012-02-03 2020-04-08 F.Hoffmann-La Roche Ag Molécules d'anticorps bispécifiques avec des lymphocytes t transfectés par un antigène et leur utilisation en médecine
BR112014025830A8 (pt) 2012-04-20 2017-10-10 Emergent Product Dev Seattle Polipeptídeos de ligação ao cd3
US9745381B2 (en) * 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
US9915665B2 (en) 2012-12-28 2018-03-13 Abbvie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
JP2016093104A (ja) * 2013-02-19 2016-05-26 国立大学法人京都大学 抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
EP3744736A1 (fr) 2013-02-20 2020-12-02 Novartis AG Ciblage efficace de la leucémie primaire humaine au moyen de lymphocytes t génétiquement modifiés des récepteurs d'antigènes chimériques anti-cd123
IL275376B2 (en) * 2013-03-11 2024-01-01 Genzyme Corp Polypeptides with hyperglycosidic bonds
US9683039B2 (en) * 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
WO2014138805A1 (fr) * 2013-03-14 2014-09-18 Csl Limited Agents anti-il-3r alpha et leurs utilisations
WO2014138819A1 (fr) 2013-03-14 2014-09-18 Csl Limited Agents qui neutralisent la signalisation par il-3 et leurs utilisations
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2970484B2 (fr) 2013-03-15 2022-09-21 Amgen Inc. Anticorps hétérodimères bispécifiques
EP2789630A1 (fr) * 2013-04-09 2014-10-15 EngMab AG Anticorps bispécifiques contre le CD3e et ROR1
US20160090416A1 (en) * 2013-05-28 2016-03-31 Numab Ag Novel antibodies
EP2839842A1 (fr) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
CA2959171C (fr) 2014-09-05 2023-11-14 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
UA126269C2 (uk) * 2015-01-23 2022-09-14 Санофі АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
AU2016262368B2 (en) 2015-05-08 2019-05-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
EA201892312A1 (ru) * 2017-03-17 2019-04-30 Санофи Триспецифические и/или тривалентные связывающие белки

Also Published As

Publication number Publication date
RS60916B1 (sr) 2020-11-30
GT201700162A (es) 2018-10-24
CL2017001866A1 (es) 2018-04-27
US20210292423A1 (en) 2021-09-23
NZ734803A (en) 2023-03-31
HUE052011T2 (hu) 2021-04-28
TN2018000324A1 (en) 2020-01-16
MY191964A (en) 2022-07-21
JP2018513831A (ja) 2018-05-31
UA126269C2 (uk) 2022-09-14
PE20171764A1 (es) 2017-12-21
EA201791666A1 (ru) 2017-11-30
EP3247725B1 (fr) 2020-07-01
AU2016210068B2 (en) 2021-10-28
SG11201705925PA (en) 2017-08-30
ES2824167T3 (es) 2021-05-11
US20180057597A1 (en) 2018-03-01
UY36536A (es) 2016-08-31
HRP20201517T1 (hr) 2020-12-11
SG10201906762YA (en) 2019-09-27
BR112017014805A2 (pt) 2018-01-09
MX2021011696A (es) 2021-10-22
DOP2017000160A (es) 2017-08-15
PH12017501190A1 (en) 2017-12-18
PL3247725T3 (pl) 2021-01-11
CL2018002490A1 (es) 2019-07-26
IL253569B2 (en) 2023-06-01
CR20170383A (es) 2017-11-22
US20180222987A1 (en) 2018-08-09
ECSP17054182A (es) 2017-11-30
MX2017009535A (es) 2017-11-02
CN107428835A (zh) 2017-12-01
AR103488A1 (es) 2017-05-10
JP6817211B2 (ja) 2021-01-20
EP4039710A2 (fr) 2022-08-10
EP3247725A1 (fr) 2017-11-29
LT3247725T (lt) 2020-10-12
TW202402802A (zh) 2024-01-16
IL299975A (en) 2023-03-01
EP3812398A3 (fr) 2021-07-21
IL253569A0 (en) 2017-09-28
JP2023093625A (ja) 2023-07-04
CO2017008462A2 (es) 2018-01-16
TWI726862B (zh) 2021-05-11
WO2016116626A1 (fr) 2016-07-28
TW202130662A (zh) 2021-08-16
CN114230668A (zh) 2022-03-25
AU2022200467A1 (en) 2022-02-17
TN2017000275A1 (en) 2018-10-19
JP7269215B2 (ja) 2023-05-08
MX2021011697A (es) 2021-10-22
TW201639885A (zh) 2016-11-16
KR20170101311A (ko) 2017-09-05
US10906978B2 (en) 2021-02-02
CN107428835B (zh) 2021-11-26
PT3247725T (pt) 2020-10-07
TN2018000325A1 (en) 2020-01-16
CN114230667A (zh) 2022-03-25
EP4039710A3 (fr) 2022-10-19
SI3247725T1 (sl) 2020-11-30
JP2021072784A (ja) 2021-05-13
CA2974453A1 (fr) 2016-07-28
EP3812398A2 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA40476A (fr) Anticorps et fragments de fixation à l&#39;antigène anti-lag3
MA38498A1 (fr) Protéines de liaison anti-lag-3
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d&#39;utilisation correspondantes
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA41669A1 (fr) Anticorps se liant a tau
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MA44334A (fr) Conjugués d&#39;anticorps comprenant un agoniste du récepteur de type toll
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
EP4249511A3 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
MA39909B1 (fr) Conjugué anticorps de l&#39;igf-1r-médicament et son utilisation pour le traitement du cancer
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
MA38161A1 (fr) Anticorps anti-bmp-6
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d&#39;utilisation
MA39090A1 (fr) Anticorps anti-ccl17
MA46988A1 (fr) Formulation liquide d&#39;anticorps anti-tnf alpha
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d&#39;utilisation